STOCK TITAN

Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis

CLDI NYSE
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
74 251 sessions, November 18, 2025 to November 18, 2026
Largest daily move
-53.1% close of March 6, 2026
1-year change
-97.8% closing prices, November 18, 2025 to November 18, 2026
1-month change
-37% closing prices, October 16, 2026 to November 18, 2026

Company Description

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is a clinical-stage immuno-oncology and biotechnology company focused on the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. According to the company’s public disclosures, Calidi is advancing systemically delivered, oncolytic virus-based genetic medicines aimed at metastatic cancer and other tumor types with high unmet medical need.

Calidi’s work is centered on its proprietary RedTail platform, which the company describes as an engineered, enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This enveloped viral technology is intended to shield the virus from immune clearance, allowing virotherapy to circulate in the body, reach tumor sites, induce tumor lysis, and deliver potent gene therapies or genetic medicines directly within the tumor microenvironment.

RedTail platform and mechanism

The RedTail platform utilizes an enveloped form of vaccinia virus that has been genetically engineered to avoid immune detection and support systemic administration. Company materials state that this design is intended to:

  • Protect the virus from immune clearance after systemic dosing
  • Enable tropism for metastatic tumor sites
  • Replicate specifically in tumor cells
  • Induce an immune priming event at the tumor site
  • Express high levels of therapeutic genetic payloads in the tumor microenvironment

Calidi has reported preclinical data in syngeneic murine models showing that the RedTail platform can remain protected from immune clearance following systemic administration, locate and replicate in tumor cells at metastatic sites, and express genetic medicines at the tumor site at levels similar to those achieved with localized dosing, while limiting systemic exposure.

Lead program: CLD-401

The company’s lead therapeutic candidate from the RedTail platform is CLD-401. Calidi describes CLD-401 as a tumor-tropic oncolytic virus designed to home to metastatic sites after systemic administration, replicate only in tumor cells, induce an immune priming event at the tumor site, and express high levels of an IL-15 superagonist in the tumor microenvironment. IL-15 superagonist is characterized by the company as a potent cytokine that induces natural killer (NK) cell and T-cell responses against tumors.

According to multiple company press releases, CLD-401 is in IND-enabling studies and is intended to target non-small cell lung cancer, head and neck cancer, ovarian cancer, and other tumor types with high unmet medical need. Calidi has highlighted preclinical data presented at the Society for Immunotherapy of Cancer (SITC) annual meeting, where CLD-401 and the RedTail platform were reported to:

  • Remain protected from immune clearance after systemic administration in syngeneic murine models
  • Find and specifically replicate in tumor cells at metastatic sites
  • Deliver IL-15 superagonist and other genetic medicines at the tumor site at concentrations comparable to localized dosing, while limiting systemic exposure

The company has also described CLD-401 as part of a broader effort to advance systemically delivered, targeted genetic medicines and has discussed pursuing strategic partnerships to support clinical development of this program and the underlying platform.

Additional virotherapy programs

In addition to CLD-401 and the RedTail platform, Calidi reports that it is developing protected virotherapies for intratumoral and localized administration. These clinical-stage programs are described as focusing on a subset of injectable cancer indications. Public descriptions also reference earlier pipeline designations such as CLD-101 for recurrent high-grade gliomas, CLD-201 for solid tumors, CLD-400 for certain lung cancer and metastatic solid tumors, and discovery research on CLD-301 for tumor indications, reflecting the company’s broader interest in oncolytic virus and stem cell-based approaches.

Corporate profile and listing

Calidi Biotherapeutics is headquartered in San Diego, California. The company’s common stock trades on the NYSE American exchange under the ticker symbol CLDI, as reflected in its SEC filings and repeated in its press releases. Calidi identifies itself as operating in the biotechnology and immuno-oncology space, with a focus on research and development of genetic medicine platforms and therapeutic candidates.

Research, collaborations, and advisory expertise

Calidi’s public communications emphasize ongoing preclinical research, IND-enabling work, and participation in scientific and investor conferences. The company has presented data on CLD-401 and the RedTail platform at the SITC Annual Meeting and has held investor-focused events around these presentations.

Calidi has also announced the establishment of a Scientific Advisory Board (SAB) composed of academic and industry experts in cancer immunotherapy, virotherapy, and IL-15-based treatments. According to company disclosures, the SAB is intended to support the development of CLD-401 and guide the evolution of the RedTail platform for systemic delivery of targeted genetic medicine.

In addition, Calidi has disclosed a partnership with Matica Biotechnology, Inc., a viral vector contract development and manufacturing organization (CDMO). Under this agreement, Matica Bio is providing analytical development, process development, and GMP manufacturing services to support the IND submission for CLD-401, reinforcing Calidi’s focus on moving its lead program toward clinical evaluation.

Capital markets and financing activity

Calidi’s SEC filings and press releases describe capital-raising activities, including an underwritten public offering of common stock units and pre-funded warrant units. The company has indicated that proceeds from such offerings are intended for working capital, general corporate purposes, and preclinical and clinical trial preparation. These disclosures, along with periodic financial reports filed with the SEC, outline Calidi’s efforts to fund its research and development programs and corporate operations.

Regulatory and development stage

Across its public statements, Calidi consistently characterizes itself as a clinical-stage company. The RedTail platform’s lead candidate, CLD-401, is described as being in IND-enabling studies, with the company indicating plans to submit an Investigational New Drug (IND) application by a specified future time frame. Additional protected virotherapy programs are described as being in clinical-stage development for intratumoral and localized administration in injectable cancer indications.

Business focus within biotechnology

Within the broader biotechnology sector, Calidi’s stated focus is on immuno-oncology and genetic medicines that use oncolytic viruses as delivery vehicles. The company’s disclosures emphasize:

  • Systemic administration of enveloped oncolytic viruses designed to evade immune clearance
  • Targeting of metastatic tumor sites
  • Induction of tumor lysis and immune priming within the tumor microenvironment
  • Delivery of potent genetic payloads, such as IL-15 superagonist, at the tumor site

This focus aligns with Calidi’s classification under research and development in biotechnology and professional, scientific, and technical services.

Use of SEC filings and public information

Investors and researchers can follow Calidi Biotherapeutics through its NYSE American listing under the symbol CLDI and through its periodic and current reports filed with the U.S. Securities and Exchange Commission. These filings, including Forms 10-K, 10-Q, 8-K, and registration statements such as Form S-1, provide additional detail on the company’s risk factors, financial condition, capital structure, and development plans.

Stock Performance

$0.5273
+0.00%
+0.0000
Pre-marketLast updated: at
-97.8%
Performance 1 year

Calidi Biotherapeutics (CLDI) closed at $0.5273 on November 18, 2026. Over the past 12 months, the price has lost 97.8%.

See what a $1,000 investment in CLDI would be worth today

Average down calculator for CLDI

CLDI Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Calidi Biotherapeutics has 10 recent news articles, with the latest published on . Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, offering, stock split. View all CLDI news →

Financial Highlights

Calidi Biotherapeutics reported operating income of -$20.2M in FY2025, and net income was -$19.9M. Diluted earnings per share stood at -$5.95. The company generated -$21.3M in operating cash flow. The current ratio was 1.59, measuring current assets divided by current liabilities.

-$19.9M
Net Income (FY2025)
-$21.3M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

YEAR
2026
2026 Regulatory

IND submission for CLD-401

Company expects to submit IND for CLD-401 by end of 2026; FDA Type D meeting feedback supportive
DEC
31
December 31, 2026 Regulatory

IND filing for CLD-401

Calidi expects to file an IND for CLD-401 by 2026-12-31 to enable clinical entry; company provided no venue or webcast details.
Q1
2027
Q1 2027 Clinical

First patient dosing

Targeted first patient dosing for CLD-401 first-in-human trial in Q1 2027; IND-enabling studies ongoing for metastatic indications.
Q1
2027
Q1 2027 Clinical

CLD-401 clinic entry

Calidi expects CLD-401 to enter clinic in Q1 2027; IND-enabling studies continue for metastatic NSCLC, H&N and other tumors.
Q1
2027
Q1 2027 Clinical

Initial patient dosing

Targeted initial patient dosing for CLD-401 first-in-human study in Q1 2027; follows FDA pre-IND alignment, trial site TBD.
YEAR
2027
2027 Clinical

Phase 1 initiation

Calidi plans Phase 1 initiation for CLD-401 in early 2027; first-in-human trial design aligned with FDA feedback.
YEAR
2027
2027 Regulatory

Australian regulatory filing

Potential parallel regulatory filing in Australia for CLD-401 around Phase 1 start; company evaluating concurrent submission.
Q2
2027
Q2 2027 Clinical

Initial patient data

Anticipated initial patient data readout from CLD-401 first-in-human study in Q2 2027; potential material clinical catalyst for investors.
MAR
21
March 21, 2028 Regulatory

Regain compliance deadline

Final deadline to regain NYSE listing compliance by Mar 21, 2028; failure to comply or have plan accepted may trigger delisting proceedings.
JUL
08
July 8, 2030 Corporate

Option fully vested

100,000-share option at $0.15 to VP Finance vests over four years; final vest expected 2030-07-08 under NYSE American rules.
MAR
01
March 1, 2033 Financial

Series G warrants expiry

Calidi Biotherapeutics has 11 upcoming scheduled events. The next event, "IND submission for CLD-401", is expected in 2026. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the CLDI stock price.

Short Interest History

Last 12 Months

Short interest in Calidi Biotherapeutics (CLDI) currently stands at 135.7 thousand shares, down 17.4% from the previous reporting period, representing 3.9% of the shares outstanding. Since the latest stock split, short interest has decreased by 56.7%, measured from August 2026.

Days to Cover History

Last 12 Months

Days to cover for Calidi Biotherapeutics (CLDI) currently stands at 2.5 days, down 40.8% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 148%. Across the settlements charted above, it has ranged from 1.0 to 6.2 days.

CLDI Company Profile & Sector Positioning

Calidi Biotherapeutics (CLDI) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NYSE.

Investors comparing CLDI often look at related companies in the same sector, including Purple Biotech Ltd. (PPBT), Clearmind Medicine Inc. (CMND), BioRestorative Therapies, Inc. (BRTX), Ernexa Therapeutics Inc. (ERNA), and Revelation Biosciences, Inc. (REVB). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CLDI's relative position within its industry.

Frequently Asked Questions

The current stock price of Calidi Biotherapeutics (CLDI) is $0.5273 in pre-market trading as of November 19, 2026.

The market cap of Calidi Biotherapeutics (CLDI) is approximately $1.8M. Learn more about what market capitalization means .

The FY2025 net income of Calidi Biotherapeutics (CLDI) is -$19.9M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Calidi Biotherapeutics (CLDI) is -$5.95 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Calidi Biotherapeutics (CLDI) is -$21.3M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Calidi Biotherapeutics (CLDI), current assets divided by current liabilities, was 1.59 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Calidi Biotherapeutics (CLDI) is -$20.2M for FY2025, its most recent completed fiscal year. Learn about operating income.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology and immuno-oncology company developing targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company focuses on systemically delivered oncolytic virus-based approaches designed to reach metastatic tumors, induce tumor lysis, and deliver genetic payloads within the tumor microenvironment.

Calidi describes its RedTail platform as a proprietary, engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. The enveloped design is intended to shield the virus from immune clearance so it can circulate, home to tumor sites, replicate in tumor cells, induce an immune priming event, and express therapeutic genetic medicines directly in the tumor microenvironment.

CLD-401 is Calidi’s first lead therapeutic candidate from the RedTail platform. It is described as a tumor-tropic oncolytic virus engineered to home to metastatic sites after systemic administration, replicate only in tumor cells, induce an immune priming event at the tumor site, and express high levels of an IL-15 superagonist in the tumor microenvironment to drive NK and T-cell responses against the tumor.

Company press releases state that CLD-401, the lead candidate from the RedTail platform, targets non-small cell lung cancer, head and neck cancer, ovarian cancer, and other tumor types with high unmet medical need.

Yes. In its public communications, Calidi Biotherapeutics identifies itself as a clinical-stage company. It reports that CLD-401 is in IND-enabling studies and that it is also developing protected virotherapies in clinical-stage development for intratumoral and localized administration in injectable cancer indications.

Calidi Biotherapeutics’ common stock is listed on the NYSE American exchange under the ticker symbol CLDI, as indicated in the company’s SEC filings and press releases.

Calidi Biotherapeutics states that it is headquartered in San Diego, California.

In addition to CLD-401 from the RedTail platform, Calidi reports that it is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration focused on a subset of injectable cancer indications. Earlier descriptions also reference pipeline candidates such as CLD-101, CLD-201, CLD-400, and discovery research on CLD-301 for tumor indications.

Calidi has reported preclinical data in syngeneic murine models presented at the Society for Immunotherapy of Cancer (SITC) annual meeting. According to the company, these data show that the RedTail platform is protected from immune clearance after systemic administration, can locate and replicate in tumor cells at metastatic sites, and can express genetic medicines at the tumor site at levels similar to localized dosing while limiting systemic exposure.

Calidi has announced a partnership with Matica Biotechnology, Inc., under which Matica Bio provides analytical development, process development, and GMP manufacturing services to support the IND submission for CLD-401. Calidi has also formed a Scientific Advisory Board composed of experts in oncology, virotherapy, and immunotherapy to help guide development of CLD-401 and the RedTail platform.